Molgramostim

Phase 3Protein / enzyme

SSavara Inc.

Molgramostim is one of 80 small molecule programs targeting Ascites. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AscitesActive, not recruiting

Autoimmune Pulmonary Alveolar ProteinosisActive, not recruiting

Pseudomyxoma PeritoneiActive, not recruiting

Cystic FibrosisActive, not recruiting

AscitesPhase 1/Phase 2

Active, not recruiting

Autoimmune Pulmonary Alveolar ProteinosisPhase 3

Active, not recruiting

Pseudomyxoma PeritoneiPhase 1

Active, not recruiting

Cystic FibrosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Molgramostim

SSavara Inc.

Phase 3

1 2

Onglyza

AstraZeneca

Preclinical

2 3

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 4

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 5

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 6

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Aztreonam Lysine

Gilead

Preclinical

5 8

Capromorelin

UUniversity of Aarhus

Preclinical

1 9

Advil

KKenvue Brands

Preclinical

1 10

Tums

Otsuka

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Autoimmune Pulmonary Alveolar Proteinosis

NCT04544293

Q4 2027

Phase 3Recruiting

Autoimmune Pulmonary Alveolar Proteinosis

NCT06431776

Q4 2034

Phase 1Recruiting

Pseudomyxoma Peritonei

NCT07341360

Clinical

Trials by Indication[1]

Autoimmune Pulmonary Alveolar Proteinosis5 trials

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Active, not recruiting·SSavara Inc.·Phase 3·NCT04544293·164 enrolled

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

Recruiting·SSavara Inc.·Phase 3·NCT06431776·5 enrolled

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis

Completed·SSavara Inc.·Phase 2·NCT02702180·139 enrolled

Show 2 more trials

Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis

Terminated·SSavara Inc.·Phase 3·NCT03482752·60 enrolled

Expanded Access to Inhaled Molgramostim Nebulizer Solution in Adults With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Available·SSavara Inc.··NCT06546098

Adult Subject1 trial

Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects

Completed·SSavara Inc.·Phase 1·NCT02468908·42 enrolled

Cystic Fibrosis1 trial

Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

Terminated·SSavara Inc.·Phase 2·NCT03597347·14 enrolled

Pseudomyxoma Peritonei1 trial

Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei

Recruiting·OOslo University Hospital·Phase 1·NCT07341360·10 enrolled

Ascites1 trial

PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

Unknown status·SSecond Affiliated Hospital of Soochow University·Phase 1/2·NCT05501340·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Molgramostim. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Molgramostim compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Molgramostim. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Savara Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: SSavara Inc.

Molgramostim

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q4 2034

Trials by Indication[1]

Autoimmune Pulmonary Alveolar Proteinosis5 trials

Adult Subject1 trial

Cystic Fibrosis1 trial

Pseudomyxoma Peritonei1 trial

Ascites1 trial

References

Drug Info

Quick Facts

Related News